Comparable Efficacy, Improved Safety and Lower Cost for High-Dose Bolus Dosing of AGGRASTAT® Compared to ReoPro® in STEMI Patients Undergoing Primary PCI: Three-Year Follow-Up for MULTISTRATEGY
Business Wire, 01.09.2010

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT® (tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro® (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

more

Medical Devices Seminar 2010: Development, Manufacturing, Release
Zürich, 06.09.2010

The seminar offers an opportunity for industry to understand the basics, interpretation, application & being update with recent changes on the standards. The seminar will cover issues related to manufacturing of products, microbiological contamination of product, clinical trial & sterilization. more